Skip to main content
Skip global navigation and go to main content

Final rule adds substances to DOT drug panel

DOT procedures to align with HHS Mandatory Guidelines

Posted November 10, 2017

U. S. Department of Transportation procedures for drug testing will be amended effective January 1, 2018, according to a final rule expected to be published in the Federal Register on November 13, 2017.

Revisions to 49 CFR Part 40 will add the following to the DOT drug-testing panel:

  • Hydrocodone,
  • Hydromorphone,
  • Oxymorphone, and
  • Oxycodone.

In addition, methylenedioxyamphetamine will be added as an initial test analyte, and methylenedioxyethylamphetamine will be removed as a confirmatory test analyte.

The revisions to Part 40 harmonize DOT regulations with the revised Mandatory Guidelines established by the U.S. Department of Health and Human Services for federal drug-testing programs for urine testing.

The changes to Part 40:

  • Clarify certain existing drug-testing program provisions and definitions,
  • Make technical amendments, and
  • Remove the requirement for employers and Consortium/Third Party Administrators to submit blind specimens.

Reasonable Suspicion Testing: What Supervisors Need to Know - DVD TrainingJ. J. Keller's Reasonable Suspicion Testing: What Supervisors Need to Know - DVD Training helps fulfill supervisors' required drug and alcohol training.


J. J. Keller's FREE Transportation SafetyClicks™ email newsletter brings quick-read safety and compliance news right to your email box.

Sign up to receive Transportation SafetyClicks™.